Diabetes mellitus is a common and frequent disease, which can cause multi-system damage for a long time, leading to chronic progressive lesions of heart, nerves, eyes, kidneys, blood vessels and other tissues, causing functional defects and failure, so effective control of blood glucose can prevent and delay the generation and development of complications. Insulin pump, also called artificial extracorporeal islet, is being widely used worldwide as an advanced means of intensive diabetes treatment, which can mimic the secretion of insulin by human pancreas and can continuously control blood glucose and glycated hemoglobin in the normal range within 24h. In the past, the traditional means of patient treatment is a “ladder therapy”, that is, the patient in the early stage of the disease, the first is to take the treatment of diet, exercise; when diabetes progresses to a certain extent, then start to take a single drug for treatment; if after a period of time, the control of this drug on the condition has declined, and does not achieve satisfactory results If after a period of time, the control of this drug decreases and does not achieve satisfactory results, the combination of multiple oral drugs is used; when oral drugs have failed to effectively control the patient’s condition, the doctors will take out their “hand” – insulin. Therefore, under the traditional treatment model, patients with type 2 diabetes requiring insulin treatment are often already in very serious condition. Between 2004 and 2006, Professor Weng Jianping, with the support of the 973 Project of the Ministry of Science and Technology and the Guangdong Provincial Department of Science and Technology, enrolled 382 type 2 diabetic patients aged 25 to 70 years old with blood glucose concentrations of 7.0 to 16.7 mmol/L from nine diabetes treatment research centers in China, and used a randomized controlled parallel group study, which is recognized as the most evidence-based method in the world. The efficacy of insulin pump treatment group or oral hypoglycemic drug treatment group for newly diagnosed type 2 diabetes was compared. The results showed that more patients in the insulin pump treatment group achieved glycemic control goals and had shorter control times than those in the oral hypoglycemic therapy group. Also, the patients’ glucose remission rate after one year was significantly improved compared to the oral group. Early intensive use of insulin therapy resulted in better recovery and maintenance of beta-cell function and better outcomes in patients with newly diagnosed type 2 diabetes compared to traditional step therapy. This research result was published in the international authoritative medical journal The Lancet on May 24, 2008. This achievement means that China has reached a world leading level in the early treatment of diabetes. Our hospital has also been using this treatment for many years and has received excellent results!